Longer Gap Between Doses Boosts Durability of Self-Amplifying mRNA H5N1 Flu Vaccine in Phase 1 Trial
A Phase 1 trial found that an eight-week dosing interval produced stronger and longer-lasting antibody responses against H5N1 influenza than ...
A Phase 1 trial found that an eight-week dosing interval produced stronger and longer-lasting antibody responses against H5N1 influenza than ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine